Previous 10 | Next 10 |
Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the presentation of data supporting clinical use of the DecisionDx ® -Melanoma test to inform decisions of whether ...
Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that it will release its financial results for the third quarter ended September 30, 2019, after the close of market on ...
Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the presentation of data supporting the ability of the DecisionDx ® -Melanoma gene expression profile (GEP) test to...
Data presented at American Academy of Ophthalmology 2019 Annual Meeting Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions in skin cancers and uveal melanoma, today announced the pr...
Study published recently in SKIN: The Journal of Cutaneous Medicine Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the publication of an expert panel consensus ...
Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that it will be added as a member of the US small-cap Russell 2000 ® Index, effective after the US market opens on...
Presentation now scheduled for 3:45 p.m. ET on Wednesday, September 4, 2019 Castle Biosciences, Inc. (Nasdaq: CSTL) today announced that its presentation at the Baird 2019 Global Healthcare Conference in New York City is now scheduled for 3:45 p.m. Eastern time on Wednesday, September...
Castle Biosciences, Inc. (CSTL) Q2 2019 Earnings Conference Call September 03, 2019 04:30 PM ET Company Participants Frank Stokes - Chief Financial Officer Derek Maetzold - Founder, President & Chief Executive Officer Conference Call Participants Catherine Schulte - Baird...
Castle Biosciences (NASDAQ: CSTL ): Q2 GAAP EPS of -$1.05 misses by $0.57 . More news on: Castle Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Q2 2019 DecisionDx-Melanoma test report volume increased 27% compared to Q2 2018 Q2 2019 recognized revenues increased to $10.7 million, up from $4.0 million in Q2 2018 Q2 2019 gross margin increased to 81%, up from 67% in Q2 2018 Castle Biosciences, Inc. (Nasdaq: CSTL)...
News, Short Squeeze, Breakout and More Instantly...
Castle Biosciences Inc. Company Name:
CSTL Stock Symbol:
NASDAQ Market:
Castle Biosciences Inc. Website:
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Canaccord Genuity 44 th Annual Growth Conference on Tuesday, Aug. 13, 2024, at ...
Campaign will focus on empowering patients impacted by melanoma Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, has joined forces with television personality, wellness coach and founder of ALL IN by Teddi, host of the...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter and six months ended June 30, 2024, after the close of market on Monday, Aug. 5, 2024. Compan...